Regarding the Execution of the Share Transfer Agreement for Kyowa Pharma Chemical Co., Ltd.

TOKYO, July 15, 2026 - Kyowa Hakko Bio Co., Ltd. (President and Representative Director: Hiroshi Nagano; hereinafter, “Kyowa Hakko Bio”), a consolidated subsidiary of Kirin Holdings Company, Limited (President and COO: Takeshi Minakata), hereby announces that it has entered into a share transfer agreement with Dai Nippon Printing Co., Ltd. (President: Yoshinari Kitajima; hereinafter, “DNP”) to transfer all shares of its wholly owned subsidiary, Kyowa Pharma Chemical Co., Ltd. (President and CEO: Hayato Miyoshi; hereinafter “Kyowa Pharma Chemical”).

1. Reasons for the Transfer

Since Kyowa Hakko Bio made Kyowa Pharma Chemical a consolidated subsidiary in 2008, Kyowa Pharma Chemical has achieved steady growth while undergoing business restructuring, thereby contributing to the enhancement of the Kirin Group’s Corporate Value.
Kyowa Pharma Chemical’s CDMO (Contract Development and Manufacturing Organization) business, which is built on the advanced technological capabilities and strong customer relationships it has developed over the years, continues to have significant growth potential. To more fully realize this potential, continuous investment and expansion under a broader business platform will be essential.
At the same time, the Kirin Group regularly reviews its balance sheet and business portfolio from a medium- to long-term perspective. As a result of careful consideration, the Kirin Group has concluded that, in order for Kyowa Pharma Chemical to further leverage its strengths and advance to the next stage of growth, developing the business under an optimal partner would be the most appropriate course of action. Accordingly, Kyowa Hakko Bio has entered into an agreement to transfer Kyowa Pharma Chemical to DNP.
Through this transfer, the Kirin Group will focus its resources on businesses where it can achieve further growth with its own organizational capabilities, thereby enhancing Corporate Value.
The impact of this transfer on the Kirin Group’s consolidated financial results is expected to be minimal.

2. Overview of Kyowa Pharma Chemical

(1) Company Name	Kyowa Pharma Chemical Co., Ltd.
(2) Address	530 Chokeiji, Takaoka City, Toyama Prefecture
(3) Title and Name of Representative	Hayato Miyoshi, President and CEO
(4) Business	Manufacture, Sale, Export, and Import of: Active Pharmaceutical Ingredients, Diagnostics, Food Additives, Feed Additives, Cosmetic Ingredients, and Fine Chemicals.
(5) Share Capital	6,276 million yen
(6) Establishment	December 29, 1951

3. Overview of DNP

(1) Company Name	Dai Nippon Printing Co., Ltd.
(2) Address	1-1-1 Ichigaya Kagacho, Shinjuku-ku, Tokyo
(3) Title and Name of Representative	Yoshinari Kitajima, President
(4) Business	Comprehensive Printing Solutions (Smart Communications, Life & Healthcare, Electronics)
(5) Share Capital	114,464 million yen
(6) Founded	October 9, 1876

4. Schedule

(1) Date of decision	July 15, 2026 (Japan Standard Time)
(2) Date of transfer	The fourth quarter of 2026 (Planned)

About Kirin Holdings

Kirin Holdings Company, Limited is a global company operating across three core business domains spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals. The company traces its roots to Japan Brewery, established in 1885, which later became Kirin Brewery in 1907. Since then, Kirin has expanded its business operations by leveraging fermentation and biotechnology as core strengths. The company entered the pharmaceutical field in the 1980s, which has since grown into a global business. In 2007, the company transitioned to a pure holding company structure as Kirin Holdings, and it is now strengthening its Non-alcoholic Beverages & Health Science domain.

Under its long-term vision “Innovate2035!”, the Kirin Group is focused on creating value that encourage behavioral change among consumers and patients, creating new lifestyle habits in the areas of food and health. With a unique business portfolio spanning Alcoholic Beverages, Non-alcoholic Beverages & Health Science, and Pharmaceuticals, the Group will further expand group-wide initiatives that support both mental and physical well-being.

The Kirin Group will continue to advance innovation through the combined strength of its people and technology, creating both social and economic value as a global leader in CSV*, while pursuing sustainable, long-term growth in corporate value.

*Creating Shared Value: combined added value for consumers as well as for society at large.